{"id":7763,"date":"2025-10-21T23:02:24","date_gmt":"2025-10-21T23:02:24","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/10\/21\/alector-dementia-drug-fails-late-stage-trial\/"},"modified":"2025-10-21T23:02:24","modified_gmt":"2025-10-21T23:02:24","slug":"alector-dementia-drug-fails-late-stage-trial","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/10\/21\/alector-dementia-drug-fails-late-stage-trial\/","title":{"rendered":"STAT+: Alector\u2019s dementia drug fails to slow patient decline in late-stage trial"},"content":{"rendered":"<p>    STAT+: Alector\u2019s dementia drug fails to slow patient decline in late-stage trial<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage study, the company announced Tuesday.<\/p>\n<p>Alector said it would lay off 49% of its employees as a result. The company employed 238 people as of last December.\u00a0<\/p>\n<p>The drug, called latozinemab, was one of several experimental drugs that had entered clinical trials for frontotemporal dementia, or FTD, a form of dementia thought to affect around 50,000 to 60,000 Americans.<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/10\/21\/alector-dementia-drug-fails-late-stage-trial\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Jason Mast<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/10\/21\/alector-dementia-drug-fails-late-stage-trial\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Alector\u2019s dementia drug fails to slow patient decline in late-stage trial An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage study, the company announced Tuesday. Alector said it would lay off 49% of its employees as a result. The company employed 238 people as [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2208,2176,2155,2152],"tags":[2150],"class_list":["post-7763","post","type-post","status-publish","format-standard","hentry","category-biotech","category-drug-development","category-pharma","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7763"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=7763"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7763\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=7763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=7763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=7763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}